Editorial
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Aug 14, 2009; 15(30): 3713-3724
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3713
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Patients who consumed > 80% of their anti-HCV medications showed a trend towards better sustained virologic response (SVR) compared to those with < 80% drug compliance (72% vs 57%, P = 0. 06). The SVR was much better in GT-1 infections (63% vs 34%, P = 0.008) but not in GT-2 or -3 infections (94% vs 95%, P = 0.88). Wk: Week.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Results of virologic response in different studies. PRESCO study 33% and 84%, respectively, at weeks 4 and 12 for GT-1 infections; APRICOT study 13% and 34%; PISG study 31% and 71% respectively. Similar figures for GT-2 and -3 infections were 47% and 92%, 37% and 72%, 84% and 96%, respectively.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 A beneficial histological response was seen in 35% and 43%, respectively, in patients with no sustained virologic response (SVR) in the ACTG and APRICOT trials. Worsening histology was seen in 18% patients with no SVR in the APRICOT study; similar data were not available in the ACTG study. In the RIBAVIC study, histological worsening was seen in 23% without SVR while histology remained stable in the remaining patients.